Humana Inc (NYSE:HUM) – Stock analysts at Piper Jaffray Companies cut their Q2 2019 earnings per share (EPS) estimates for shares of Humana in a research report issued to clients and investors on Wednesday, November 7th. Piper Jaffray Companies analyst S. James now forecasts that the insurance provider will post earnings of $4.78 per share for the quarter, down from their previous forecast of $4.96. Piper Jaffray Companies has a “Overweight” rating and a $380.00 price target on the stock. Piper Jaffray Companies also issued estimates for Humana’s Q4 2019 earnings at $3.30 EPS, FY2019 earnings at $17.20 EPS, Q2 2020 earnings at $5.62 EPS and FY2020 earnings at $19.60 EPS.

HUM has been the subject of a number of other research reports. Zacks Investment Research lowered Humana from a “buy” rating to a “hold” rating in a research report on Friday, October 5th. Bank of America raised their price objective on Humana from $338.00 to $375.00 and gave the company a “buy” rating in a research report on Thursday, August 2nd. Royal Bank of Canada raised their price objective on Humana from $318.00 to $349.00 and gave the company a “sector perform” rating in a research report on Thursday. SunTrust Banks raised their price objective on Humana to $380.00 and gave the company a “hold” rating in a research report on Wednesday, September 19th. Finally, Cowen initiated coverage on Humana in a research report on Monday, September 17th. They set a “market perform” rating and a $372.00 price objective for the company. Seven investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Humana currently has an average rating of “Buy” and an average target price of $352.30.

Shares of Humana stock opened at $338.95 on Friday. The stock has a market cap of $48.77 billion, a PE ratio of 25.36, a PEG ratio of 1.73 and a beta of 1.03. The company has a quick ratio of 1.43, a current ratio of 1.43 and a debt-to-equity ratio of 0.47. Humana has a twelve month low of $231.90 and a twelve month high of $355.88.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share for the quarter, beating the Zacks’ consensus estimate of $4.29 by $0.29. The firm had revenue of $14.21 billion during the quarter, compared to analyst estimates of $13.97 billion. Humana had a return on equity of 19.36% and a net margin of 2.70%. During the same quarter last year, the business posted $3.39 earnings per share.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC lifted its stake in Humana by 1.4% in the third quarter. FMR LLC now owns 12,379,797 shares of the insurance provider’s stock worth $4,190,809,000 after purchasing an additional 167,283 shares during the last quarter. BlackRock Inc. lifted its stake in Humana by 1.2% in the third quarter. BlackRock Inc. now owns 12,311,736 shares of the insurance provider’s stock worth $4,167,767,000 after purchasing an additional 140,731 shares during the last quarter. Northern Trust Corp lifted its stake in Humana by 1.2% in the second quarter. Northern Trust Corp now owns 1,687,211 shares of the insurance provider’s stock worth $502,164,000 after purchasing an additional 20,480 shares during the last quarter. Acadian Asset Management LLC lifted its stake in Humana by 7.6% in the second quarter. Acadian Asset Management LLC now owns 1,324,681 shares of the insurance provider’s stock worth $394,262,000 after purchasing an additional 93,021 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its stake in Humana by 4.7% in the third quarter. Massachusetts Financial Services Co. MA now owns 804,090 shares of the insurance provider’s stock worth $272,199,000 after purchasing an additional 35,845 shares during the last quarter. Institutional investors own 92.62% of the company’s stock.

In related news, CEO Bruce D. Broussard sold 18,000 shares of Humana stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $328.66, for a total value of $5,915,880.00. Following the completion of the transaction, the chief executive officer now owns 71,085 shares in the company, valued at $23,362,796.10. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Elizabeth D. Bierbower sold 3,092 shares of Humana stock in a transaction dated Thursday, August 16th. The stock was sold at an average price of $330.00, for a total value of $1,020,360.00. Following the completion of the transaction, the insider now owns 14,289 shares of the company’s stock, valued at approximately $4,715,370. The disclosure for this sale can be found here. Company insiders own 0.60% of the company’s stock.

The business also recently declared a quarterly dividend, which will be paid on Friday, January 25th. Investors of record on Monday, December 31st will be given a $0.50 dividend. The ex-dividend date is Friday, December 28th. This represents a $2.00 annualized dividend and a yield of 0.59%. Humana’s dividend payout ratio is currently 17.08%.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Read More: Determine Your Level of Risk Tolerance

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.